» Articles » PMID: 35331312

Epigenetic Remodelling in Human Hepatocellular Carcinoma

Overview
Publisher Biomed Central
Specialty Oncology
Date 2022 Mar 25
PMID 35331312
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinoma (HCC) is the most frequent primary liver cancer, being the sixth most commonly diagnosed cancer and the fourth leading cause of cancer-related death. As other heterogeneous solid tumours, HCC results from a unique synergistic combination of genetic alterations mixed with epigenetic modifications.In HCC the patterns and frequencies of somatic variations change depending on the nearby chromatin. On the other hand, epigenetic alterations often induce genomic instability prone to mutations. Epigenetics refers to heritable states of gene expression without alteration to the DNA sequence itself and, unlike genetic changes, the epigenetic modifications are reversible and affect gene expression more extensively than genetic changes. Thus, studies of epigenetic regulation and the involved molecular machinery are greatly contributing to the understanding of the mechanisms that underline HCC onset and heterogeneity. Moreover, this knowledge may help to identify biomarkers for HCC diagnosis and prognosis, as well as future new targets for more efficacious therapeutic approaches.In this comprehensive review we will discuss the state-of-the-art knowledge about the epigenetic landscape in hepatocarcinogenesis, including evidence on the diagnostic and prognostic role of non-coding RNAs, modifications occurring at the chromatin level, and their role in the era of precision medicine.Apart from other better-known risk factors that predispose to the development of HCC, characterization of the epigenetic remodelling that occurs during hepatocarcinogenesis could open the way to the identification of personalized biomarkers. It may also enable a more accurate diagnosis and stratification of patients, and the discovery of new targets for more efficient therapeutic approaches.

Citing Articles

Novel histone modifications and liver cancer: emerging frontiers in epigenetic regulation.

Wang Z, Liu Z, Lv M, Luan Z, Li T, Hu J Clin Epigenetics. 2025; 17(1):30.

PMID: 39980025 PMC: 11841274. DOI: 10.1186/s13148-025-01838-8.


B4GALNT1 Regulates Hepatocellular Carcinoma Cell Proliferation and Apoptosis via the PI3K-AKT-mTOR Pathway.

Bie L, Chen G, Lei X, Xiao F, Xu Z, Xiang Z J Clin Lab Anal. 2025; 39(4):e25155.

PMID: 39829207 PMC: 11848214. DOI: 10.1002/jcla.25155.


Digestive cancers: mechanisms, therapeutics and management.

Zhan T, Betge J, Schulte N, Dreikhausen L, Hirth M, Li M Signal Transduct Target Ther. 2025; 10(1):24.

PMID: 39809756 PMC: 11733248. DOI: 10.1038/s41392-024-02097-4.


A review of deep learning models for the prediction of chromatin interactions with DNA and epigenomic profiles.

Wang Y, Kong S, Zhou C, Wang Y, Zhang Y, Fang Y Brief Bioinform. 2024; 26(1).

PMID: 39708837 PMC: 11663014. DOI: 10.1093/bib/bbae651.


Antimicrobial activity and cytotoxic and epigenetic effects of tannic acid-loaded chitosan nanoparticles.

Rashidipour M, Abbaszadeh S, Birjandi M, Pajouhi N, Ahmadi Somaghian S, Goudarzi G Sci Rep. 2024; 14(1):30405.

PMID: 39638815 PMC: 11621443. DOI: 10.1038/s41598-024-80771-x.


References
1.
Wang Y, Yang Y, Gao H, Ouyang T, Zhang L, Hu J . Comprehensive Analysis of CDCAs Methylation and Immune Infiltrates in Hepatocellular Carcinoma. Front Oncol. 2021; 10:566183. PMC: 7921702. DOI: 10.3389/fonc.2020.566183. View

2.
Tomaselli D, Lucidi A, Rotili D, Mai A . Epigenetic polypharmacology: A new frontier for epi-drug discovery. Med Res Rev. 2019; 40(1):190-244. PMC: 6917854. DOI: 10.1002/med.21600. View

3.
Liu Y, Zhang Y, Xiao B, Tang N, Hu J, Liang S . MiR-103a promotes tumour growth and influences glucose metabolism in hepatocellular carcinoma. Cell Death Dis. 2021; 12(6):618. PMC: 8206076. DOI: 10.1038/s41419-021-03905-3. View

4.
Shen Z, Chen Y, Huang G, Zhu X, Wang R, Chen L . Aurora-a confers radioresistance in human hepatocellular carcinoma by activating NF-κB signaling pathway. BMC Cancer. 2019; 19(1):1075. PMC: 6842208. DOI: 10.1186/s12885-019-6312-y. View

5.
Lo Re O, Vinciguerra M . Histone MacroH2A1: A Chromatin Point of Intersection between Fasting, Senescence and Cellular Regeneration. Genes (Basel). 2017; 8(12). PMC: 5748685. DOI: 10.3390/genes8120367. View